Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. - Wikidata - wikimedia - TriplyDB

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

http://www.wikidata.org/entity/Q42440513

about

Ixabepilone for the treatment of solid tumors: a review of clinical data Ixabepilone: a new antimitotic for the treatment of metastatic breast cancer.Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma.Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins.Novel microtubule-targeting agents - the epothilones.Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group The epothilones: new therapeutic agents for castration-resistant prostate cancer.Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.Epothilones in epithelial ovarian, fallopian tube, or primary peritoneal cancer: a systematic review.The epothilone B analogue ixabepilone in patients with advanced hepatobiliary cancers: a trial of the University of Chicago Phase II Consortium.Susan Bates, M.D., and Antonio "Tito" Fojo, M.D., Ph.D.: Thirty Years of Research, Discovery, Service, and Mentorship at the National Cancer Institute.Epothilones in the treatment of cancer.Emerging drugs to replace current leaders in first-line therapy for breast cancer.Evaluation of the Safety and Benefit of Phase I Oncology Trials for Patients With Primary CNS Tumors.Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors Ixabepilone: a new microtubule-targeting agent for breast cancer.Ixabepilone for the treatment of taxane-refractory breast cancer.Dose escalation methods in phase I cancer clinical trials.Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.Epothilones in breast cancer: current status and future directions.A phase I/II trial and pharmacokinetic study of ixabepilone in adult patients with recurrent high-grade gliomas.Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone.Ixabepilone as monotherapy or in combination for the treatment of advanced breast cancer.The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer.Ixabepilone: a new active chemotherapy in the treatment of breast cancer.The epothilones: how pharmacology relates to clinical utility.Advances in breast cancer treatment: the emerging role of ixabepilone.Ixabepilone for the treatment of breast cancer.Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?Emerging mitotic inhibitors for non-small cell carcinoma.Evaluation of the pharmacokinetics of ixabepilone for the treatment of breast cancer.Ixabepilone for the treatment of endometrial cancer.Epothilones and new analogues of the microtubule modulators in taxane-resistant disease

P2860

Q28271570-0B650BB2-7132-47AC-8279-D429F4D52E07 Q33380465-335C2ECC-D6E1-497E-AD4E-2D7FB78BDC71 Q33400047-7623412C-9334-44F0-AC33-64417EA6A973 Q33510328-963006C9-1013-4E20-90DD-199028018F78 Q33999018-219064DE-D381-4561-B79E-0F9642B23180 Q34611212-E7E6D9BE-66BE-4008-A16A-167FC72080E9 Q34611801-B482EF79-22FD-4563-8FD0-F0DABD550A5D Q34788890-A2494062-AA2C-42F7-999C-71333448CBB1 Q34915389-33C76AAD-4E7F-4873-AEF6-F1AC76CD91DF Q35584399-B3862822-A961-4A8B-894B-BD6DA0687DDB Q35884220-F0637CB8-86E4-417F-853D-0EC97E9579CC Q35997562-1F728D6A-17DF-400A-85D8-30495C84BC9A Q36255706-D3F0DAA8-B734-4DB1-82CB-6453C695D752 Q36478750-65848999-A7DC-4062-9E37-9FCB87CD5821 Q36491842-5204C7F7-7C2A-45E8-828E-31B5F873936F Q36580598-96877B59-6FE4-42F7-86C8-981195E7286E Q36871155-2B6DD1D8-A080-4E41-AD07-FCC8B6896AE0 Q37104791-64ED6965-1FCE-456F-A169-9328B9F2942A Q37159488-45330B17-A580-4130-B6BB-88E683B61656 Q37179381-240AC3D3-0FF2-470A-8047-61A8DC01FF22 Q37198192-7761E277-5601-41E2-8003-BCF3AEC8329D Q37236419-08D2D952-373B-43F6-8B2B-2BABC8EADF93 Q37242676-E4121F6D-6DE4-414F-8BAE-B88B54BB1504 Q37262792-72D76079-EBC0-4E35-8615-174A9BBBD736 Q37290709-9964C0F9-8C8A-43F6-8277-5096B659D269 Q37321909-D792D09A-40B6-40DE-9A16-4483D97EA7B2 Q37356274-FFB40EB4-D7C0-4A20-B0F1-CE097D74DCD1 Q37378233-37803622-D24B-4E31-BB2F-56B8343F88C7 Q37401833-973B28AB-FB75-4E87-8D86-BA38E62FC923 Q37543912-92A18207-2FAE-42D5-ACB2-6942B1061390 Q37656206-F85F69F5-6F83-4E26-8DF6-E1F07D086CDB Q37876407-2598A477-CE51-4B6E-A915-44E1F001ADB1 Q38069185-AA1310A7-B78F-4019-B841-C8F878BDC683 Q38085327-531BCFD8-B5ED-4290-ABC4-5798046F38E3 Q38527538-819034E3-7452-48AA-91CA-21F88B1A90D6 Q38763500-04A7A8CE-591D-4BAE-9003-5085C41CF50A Q57244875-654AAC76-53A7-4ACF-92A8-E7343D1E3F7A

P2860

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

http://www.wikidata.org/entity/Q42440513

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Phase I trial and pharmacokine ...... daily schedule for five days.

@en

Phase I trial and pharmacokine ...... daily schedule for five days.

@nl

type

label

Phase I trial and pharmacokine ...... daily schedule for five days.

@en

Phase I trial and pharmacokine ...... daily schedule for five days.

@nl

prefLabel

Phase I trial and pharmacokine ...... daily schedule for five days.

@en

Phase I trial and pharmacokine ...... daily schedule for five days.

@nl

P1433

Q42440513-D51338BF-12C6-471E-B881-2B408CCBFE75

P1476

Q42440513-5FC6FA93-74CF-45EF-8332-37EA53D69CF2

P2093

Q42440513-1CC13F28-8639-463B-A1A3-14E1EE575959

Q42440513-3ED0A3AC-AE20-40AD-8C6B-2D221D104EC1

Q42440513-647D0179-91B4-4933-BB6F-54214086FF80

Q42440513-82A6CEF2-54A3-4786-B625-2DDE2D86AD01

Q42440513-8A0181DB-E305-482B-8CF5-DC53E6FCD398

Q42440513-8C4C9111-D352-4911-829E-0E303255573B

Q42440513-A89EA44C-C17D-4981-B4BA-7C3DC3204C74

Q42440513-A8A05672-3497-4AE6-8F3E-F22976A23385

Q42440513-EFB4CDC7-CA6F-4464-81BD-501520CD961D

Q42440513-F2ACDA8B-99F6-48DB-AA10-96E8958BDE93

P304

Q42440513-73EDC8A8-09B0-4F03-859F-81049640024A

P31

Q42440513-064B679D-0F6C-4B66-9524-02FDBCE3AED1

P356

Q42440513-3E4B1311-203C-49A5-B58F-44B1E18E6306

P407

Q42440513-638597FF-8AE3-4ECB-905F-C500AFC18A24

P433

Q42440513-7DA0546E-4190-4D4D-AE52-A7C171C9F0F2

P478

Q42440513-EB67FA86-370E-459B-9D6A-47155318AE5B

P50

Q42440513-3B09A841-7EA3-4460-B188-4A00EA2F7CAB

P577

Q42440513-B57B06D3-62D8-45F1-8F24-F428BFEC9269

P698

Q42440513-C966F395-BE5A-4D7A-8E5A-A45BB762F31E

P921

Q42440513-A40349E8-F4B4-4CD9-9F7A-9EFB5DBC0819

P356

JCO.2003.03.063

P1433

Journal of Clinical Oncology

P1476

Phase I trial and pharmacokine ...... a daily schedule for five days

@en

P2093

Ann Rutt

http://www.w3.org/2001/XMLSchema#string

Bharat Damle

http://www.w3.org/2001/XMLSchema#string

Brigitte Widemann

http://www.w3.org/2001/XMLSchema#string

Daryl Sonnichsen

http://www.w3.org/2001/XMLSchema#string

David Lebwohl

http://www.w3.org/2001/XMLSchema#string

Herb Kotz

http://www.w3.org/2001/XMLSchema#string

Jame Abraham

http://www.w3.org/2001/XMLSchema#string

Louis Davis

http://www.w3.org/2001/XMLSchema#string

Manish Agrawal

http://www.w3.org/2001/XMLSchema#string

Maureen Edgerly

http://www.w3.org/2001/XMLSchema#string

P304

1866-1873

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2003.03.063

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12721265

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial